Enveric Biosciences (NASDAQ:ENVB) Lowered to “Sell” Rating by Wall Street Zen

Enveric Biosciences (NASDAQ:ENVB) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Enveric Biosciences Price Performance

ENVB opened at $1.42 on Friday. The stock has a market capitalization of $5.21 million, a price-to-earnings ratio of -0.06 and a beta of 1.11. The business has a 50-day moving average of $2.44 and a two-hundred day moving average of $2.90. Enveric Biosciences has a 12 month low of $1.26 and a 12 month high of $17.64.

Enveric Biosciences (NASDAQ:ENVB) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.08) EPS for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.